Compare Incyte Corporation (INCY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Otis Worldwide Corp — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while Otis Worldwide Corp trades at $72.47 (market cap $28.20B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.31% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OTIS | |
|---|---|---|
Market Cap | $23.11B | $28.20B |
Sector | Health | Industrials |
52-Week High | $118.52 | $100.99 |
52-Week Low | $67.38 | $69.34 |
Enterprise Value | $19.13B | $35.58B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Otis Worldwide trades at $73.49, showing minimal daily movement with a slight 0.05% gain. The stock maintains a bullish technical signal, supported by moving averages, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing estimates despite service growth. The company continues strategic initiatives, including dividend increases and modernization projects, as highlighted in recent corporate announcements.
Outlook remains cautiously optimistic with a consensus price target of $91, offering significant upside. Risks include margin pressures from tariffs and regional delays, but strong service revenue growth and a reasonable valuation provide a foundation for recovery. Investors should weigh near-term headwinds against long-term operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
